Previous 10 | Next 10 |
LOS ANGELES, March 24, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announ...
Capricor Therapeutics, Inc. (CAPR) Q4 2019 Earnings Conference Call March 18, 2020, 04:30 PM ET Company Participants AJ Bergmann - CFO Linda Marban - President and CEO Conference Call Participants Joseph Pantginis - H.C. Wainwright Jason McCarthy - Maxim Group Presentati...
Capricor Therapeutics (NASDAQ: CAPR ): Q4 GAAP EPS of -$0.34 in-line. More news on: Capricor Therapeutics, Inc., Earnings news and commentary, Healthcare stocks news, , Read more ...
-To Report Final 12-month HOPE-2 Data in the Second Quarter- -Exosomes Platform Technology Expanded to Potentially Combat the Novel Coronavirus- -To Host Conference Call and Webcast Today at 4:30 p.m. ET- LOS ANGELES, March 18, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics ...
Biomerica (NASDAQ: BMRA ) +133% on advancement of rapid coronavirus test. More news on: Biomerica, Inc., IMV Inc., Vaxart, Inc., Stocks on the move, , Read more ...
LOS ANGELES, March 17, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy (DMD) and other rare disorders, today announc...
LOS ANGELES, March 11, 2020 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR) a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders will release its fin...
Introduction Back in the 1990s, ThermoGenesis Holdings Inc. ( THMO ) was one of the early public company pioneers seeking to bring stem cell and regenerative medicine therapies to the market when it traded under the symbol KOOL. Primarily a cell processing device company, it eventually i...
LOS ANGELES, Dec. 19, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today anno...
LOS ANGELES, Dec. 17, 2019 (GLOBE NEWSWIRE) -- Capricor Therapeutics, Inc. (NASDAQ: CAPR), a clinical-stage biotechnology company focused on the development of first-in-class biological therapeutics for the treatment of Duchenne muscular dystrophy and other rare disorders, today anno...
News, Short Squeeze, Breakout and More Instantly...
Capricor Therapeutics Inc. Company Name:
CAPR Stock Symbol:
NASDAQ Market:
Capricor Therapeutics Inc. Website:
SAN DIEGO, July 01, 2024 (GLOBE NEWSWIRE) -- Capricor Therapeutics (NASDAQ: CAPR), a biotechnology company developing transformative cell and exosome-based therapeutics for the treatment of rare diseases, today announced that the Company is set to join the Russell 2000 ® Index an...
-Results in Performance of the Upper Limb (PUL v2.0) Continue to Show Slowing of Disease Progression in Later-Stage DMD Patients- -Improvements Seen in Multiple Cardiac Endpoints Demonstrating Stabilization of Cardiac Function Over 3 Years of Treatment- -Pre-BLA Meeting with FDA...
SAN DIEGO, June 25, 2024 (GLOBE NEWSWIRE) -- In a release issued under the headline "Capricor Therapeutics Announces for the Treatment of Duchenne Muscular Dystrophy" on Tuesday, June 25th by Capricor Therapeutics, please note that the words "Pre-BLA Meeting with FDA for Deramiocel" were omitted ...